Phenotype of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance

Neoplasma

Volumn 56, Issue 6, 2009, Pages 526-532

  Kovarova, L ^a,b   Buresova, I ^a,b   Buchler, T ^c   Suska, R ^a,b   Pour, L ^a,b   Zahradova, L ^a   Penka, M ^a   Hajek, R ^a,b  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c FAKULTNÍ THOMAYEROVA NEMOCNICE   (Czech Republic)

Author keywords

Flow cytometry; Monoclonal gammopathy; Multiple myeloma; Plasma cells

Indexed keywords

CD19 ANTIGEN; CD38 ANTIGEN; CD56 ANTIGEN; SYNDECAN 1;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CANCER STAGING; CELL PROLIFERATION; DIFFERENTIAL DIAGNOSIS; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PHENOTYPE; PLASMA CELL; IMMUNOLOGY; MIDDLE AGED; PARAPROTEINEMIA; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD19; ANTIGENS, CD38; ANTIGENS, CD56; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PARAPROTEINEMIAS; PHENOTYPE; PLASMA CELLS; PROGNOSIS; SYNDECAN-1;

EID: 70449714002     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2009_06_526     Document Type: Article

References (30)

1. ROBILLARD N, PELLAT-DECEUNYNCK C, BATAILLE R. Phenotypic characterization of the human myeloma cell growth fraction. Blood 2005; 105: 4845-4848. doi:10.1182/blood-2004-12-4700
2. SAN MIGUEL JF, BLADÉ CJ, GARCÍA-SANZ R. Treatment of multiple myeloma. Haematologica 1999; 84: 36-58.
3. KYLE RA, RAJKUMAR SV. Monoclonal gammopathy of undetermined significance. Br J Haematol 2006; 134: 573-589. doi:10.1111/j.1365-2141.2006.06235.x
4. HALLEK M, BERGSAGEL PL, ANDERSON KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91: 3-21.
5. DURIE BG, SALMON SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842-854. doi:10.1002/1097-0142(197509)36:3〈842::AID-CNCR2820360303〉3.0.CO;2-U
6. GREIPP PR , SAN MIGUEL J, DURIE BG et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420. doi:10.1200/JCO.2005.04. 242
7. SCUDLA V, ZEMANOVA M, MINARIK J et al. International prognostic index (IPI) - a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy. Neoplasma 2006; 53: 277-284.
8. PÉREZ-PERSONA E, VIDRIALES MB, MATEO G et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007; 110: 2586-2592. doi:10.1182/blood-2007- 05-088443
9. GERTZ MA. Relevant prognostic features of multiple myeloma and the new International Staging System. Leuk Lymphoma 2007; 48: 458-468. doi:10.1080/10428190601059753
10. MATEO G, MONTALBÁN MA, VIDRIALES MB et al.; PETHEMA Study Group; GEM Study Group. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol. 2008; 26: 2737-2744. doi:10.1200/JCO.2007. 15.4120
11. VAN CAMP B, DURIE BG, SPIER C et al. Plasma Cells in Multiple Myeloma Express a Natural Killer Cell-Associated Antigen: CD56 (NKH-1; Leu-19). Blood 1990; 76: 377-382.
12. RAWSTRON AC, OWEN RG, DAVIES FE et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol 1997; 97: 46-55. doi:10.1046/j.1365-2141.1997.72653.x
13. MATEO G, CASTELLANOS M, RASILLO A et al. Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res 2005; 11: 3661-3667. doi:10.1158/1078-0432.CCR-04-1489
14. OCQUETEAU M, ORFAO A, ALMEIDA J et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 1998; 152: 1655-1665.
15. SEZER O, HEIDER U, ZAVRSKI I et al. Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells. Haematologica 2001; 86: 837-843.
16. CHANG H, SAMIEE S, YI QL. Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant. Leuk Lymphoma 2006; 47: 43-47. doi:10.1080/10428190500272549
17. SAHARA N, IHARA M, ONO T. Multiple Myeloma Expressing CD19+CD56- Phenotype. Am J Hematol 2000; 64: 311-313. doi:10.1002/1096-8652(200008)64: 4〈311::AID-AJH13〉 3.0.CO;2-U
18. RAWSTRON AC, DAVIES FE, DASGUPTA R et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood. 2002; 100: 3095-3100. doi:10.1182/blood-2001-12-0297
19. SAN MIGUEL JF, ALMEIDA J, MATEO G et al. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood 2002; 99: 1853-1856. doi:10.1182/blood.V99.5.1853
20. PAIVA B, VIDRIALES MB, CERVERO J et al. Multiparameter flow cytometric remission is the most relevant factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008; 112: 4017-4023. doi:10.1182/blood-2008-05-159624
21. LIU H, YUAN C, HEINERICH J et al. Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study. Leuk Lymphoma. 2008; 49: 306-314. doi:10.1080/10428190701813018
22. RAWSTRON AC, ORFAO A, BEKSAC M et al.; on behalf of the European Myeloma Network. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008; 93: 431-438. doi:10.3324/haematol.11080
23. PELLAT-DECEUNYNCK C, BARILLE S, PUTHIER D et al. Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization. Cancer Res 1995; 55: 3647-3653.
24. WITZIG TE, GERTZ MA, LUST JA et al. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Bl ood 1996; 88: 1780-1787.
25. NOWAKOWSKI GS, WITZIG TE, DINGLI D et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 2005; 106: 2276-2279. doi:10.1182/blood-2005- 05-1858
26. VANDE BROEK I, VANDERKERKEN K, VAN CAMP B et al. Extravasation and homing mechanisms in multiple myeloma. Clin Exp Metastasis 2008; 25: 325-334. doi:10.1007/s10585-007-9108-4
27. ZHOU LJ, SMITH HM, WALDSCHMIDT TJ et al. Tissue-specific expression of the human CD19 gene in transgenic mice inhibits antigen-independent B-lymphocyte development. Mol Cell Biol 1994; 14: 3884-3894.
28. ISHIKAWA H, TSUYAMA N, MAHMOUD MS et al. CD19 expression and growth inhibition of tumours in human multiple myeloma. Leuk Lymphoma 2002; 43: 613-616. doi:10.1080/10428190290012146
29. SAHARA N, TAKESHITA A. Prognostic significance of surface markers expressed in multiple myeloma: CD56 and other antigens. Leuk Lymphoma 2004; 45: 61-65. doi:10.1080/1042819031000149377
30. BATAILLE R, JEGO G, ROBILLARD N et al. The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica 2006; 91: 1234-1240.